3rd Quarter - Amendment
AVANIR PHARMACEUTICALS for AVANIR PHARMACEUTICALS
Client
Income
—
Expenses
$130,000
Expense method
A: Lobbying Disclosure Act definitions
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Oct 7, 2015 | $60,000 | Replaced |
| 3rd Quarter - Amendment (this page) | Feb 5, 2016 | $130,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
SGR Repeal, 21st Century Cures, Specialty Tier Price Cap Legislation, Patent Reform, Health Care Quality Measures
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CHRISTINE D'ORSIE | Director of Advocacy |
| CRYSTAL LYNN VANUCH | Head of Government Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.